J. Safra Sarasin Holding AG Purchases Shares of 7,011 QIAGEN N.V. $QGEN

Key Points

• J. Safra Sarasin Holding AG has acquired 7,011 shares of QIAGEN N.V., valued at approximately $336,000, as revealed in its recent SEC filing.
• Major institutional investors, including Price T Rowe Associates and Wellington Management Group, have significantly increased their stakes in QIAGEN, indicating robust interest in the company.
• QIAGEN recently reported quarterly earnings meeting analysts' expectations, with a revenue increase of 7.7% year-over-year, and has set its FY 2025 earnings guidance at $2.350 EPS.

J. Safra Sarasin Holding AG purchased a new stake in QIAGEN N.V. (NYSE:QGEN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 7,011 shares of the company's stock, valued at approximately $336,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of QGEN. Price T Rowe Associates Inc. MD raised its stake in shares of QIAGEN by 3,030.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company's stock valued at $179,501,000 after purchasing an additional 4,327,934 shares during the period. Wellington Management Group LLP raised its stake in shares of QIAGEN by 12.2% in the 1st quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock valued at $972,191,000 after purchasing an additional 2,656,136 shares during the period. Deutsche Bank AG raised its stake in shares of QIAGEN by 57.5% in the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock valued at $180,319,000 after purchasing an additional 1,639,621 shares during the period. Nuveen LLC acquired a new stake in shares of QIAGEN in the 1st quarter valued at about $44,078,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of QIAGEN in the first quarter valued at about $13,463,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on QGEN shares. Wall Street Zen downgraded QIAGEN from a "buy" rating to a "hold" rating in a research report on Friday. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of QIAGEN in a research report on Saturday, September 27th. Bank of America lifted their target price on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. UBS Group lifted their target price on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Finally, Barclays set a $53.00 target price on QIAGEN and gave the company an "overweight" rating in a research report on Thursday. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, QIAGEN has a consensus rating of "Hold" and an average target price of $49.40.

QIAGEN Trading Up 1.3%

QIAGEN stock opened at $46.83 on Friday. QIAGEN N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The stock has a market capitalization of $10.41 billion, a P/E ratio of 27.67, a PEG ratio of 2.47 and a beta of 0.66. The stock has a 50-day simple moving average of $47.43 and a 200 day simple moving average of $45.28.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting analysts' consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The business had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same quarter last year, the company posted $0.55 earnings per share. QIAGEN's quarterly revenue was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Analysts expect that QIAGEN N.V. will post 2.26 earnings per share for the current year.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QIAGEN N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.